The week in pharma: action, reaction and insight – week to March 8, 2024

10 March 2024
tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

Germany’s Bayer has entered into deal with USA-based BridgeBio Pharma to commercialize its cardiovascular candidate acoramidis worth $310 million in upfront and milestone payments. Research news last week included Denmark’s Novo Nordisk releasing positive new data on its semaglutide, showing it cut kidney-disease related events in diabetes patients by 24%. Also, Singapore-based TauRx Pharma released new data on its Alzheimer’s candidate hydromethylthionine mesylate (HMTM). US President Joe Biden is moving further with his intent to bring down drug prices in the USA, with plans not to limit Medicare negotiations to just 20 drugs a year.

Bayer deal bolsters BridgeBio’s EU commercial position and balance sheet

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical